Our work suggests that TAGLN2, YBX1 and induced ISGs are novel predictive markers for clinical outcomes, and that targeting TAGLN2-mediated ISG upregulation is an attractive therapeutic sensitization strategy for gastric cancer patients. The gene discussed is YBX1; the disease is gastric cancer.